Back to search

Article

Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple Myeloma

2025-04-19

Abstract excerpt

Targeted immunotherapies against B-cell maturation antigen (BCMA) have transformed the treatment landscape of Multiple Myeloma (MM). Fc receptor-like 5 (FCRL5) has emerged as an alternative target. However, resistance frequently emerges within months, posing a significant clinical challenge. Structural alterations and mutations in BCMA only account for the minority of cases and insights into BCMA antigen escape r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6a62d7f2-2280-5a5f-b4e6-002f70dddace
DOI
10.1101/2025.04.15.25325788
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple MyelomaDOI 10.1101/2025.04.15.25325788
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity
Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass StudySemantic proximity
Epigenetic Plasticity Drives Carcinogenesis and Multi-Therapy Resistance in Multiple MyelomaSemantic proximity
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity
Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MMSemantic proximity
Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myelomaSemantic proximity
Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?Semantic proximity
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.Semantic proximity
Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities.Semantic proximity
Utilizing Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma High-Risk SubgroupsSemantic proximity
Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistanceSemantic proximity
Select a neighboring publication to make it the new centre.